NGF and hematologic disorder: A prospective study of 45 patients with hematologic malignancies treated with bortezomib, thalidomide, or vincristine, also found there was a significant decrease in NGF in participants who developed CIPN symptoms, whereas there was no change in NGF in participants who did not develop CIPN symptoms (25).